Stamulumab
Based on 1 publication(s) in Google Scholar
Stamulumab (MYO-029) is a recombinant human IgG1λ antibody that binds to myostatin and neutralizes its activity by preventing binding to its endogenous high-affinity receptor ActRIIB. Stamulumab leads to muscle fiber hypertrophy and not hyperplasia in SCID mice. Stamulumab has the potential for Becker muscular dystrophy (BMD), facioscapulohumeral dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD) research.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 95.07%
- No. CAS: 705287-60-1
- Peso molecular:142.56 kDa
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Pureza y Documentación
- Referencias
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Stamulumab
More
Actividad biológica
Human IgG1 lambda2
Human
MSTN
Stamulumab (i.v.; 1, 5, 20, 100 mg/kg/week for 4 weeks) has a central clearance (CL) of 0.25 mL/h/kg in C57/SCID mice[1].
Pharmacokinetic Parameters of Stamulumab (MYO-029)[1].
| C57/SCID mice IV (1-100 mg/kg/week for 4 weeks) | Sprague Dawley rats (2-50 mg/kg; single injection) | Cynomolgus monkeys (10-100 mg/kg/week for 5 or 39 weeks) | |
| CL (mL/h/kg) | 0.245 | 0.542 | 0.228 |
| Volume of central compartment (mL/kg) | 103 | 58.9 | 41.8 |
| Distributive clearance (mL/h/kg) | 1.79 | 0.815 |
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female SCID mice[1]
-
Dosage:1, 2.5, 5, 10 mg/kg
-
Administration:IP; every week for 12 weeks
-
Result:Increased skeletal muscle mass in vivo in a concentration‐dependent manner.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 lambda2
ELISA, FACS, Functional assay
Chemical Information
-
No. CAS 705287-60-1
-
Appearance Liquid
-
Peso molecular 142.56 kDa
-
Color Colorless to light yellow
-
SMILES
[Stamulumab]
-
Synonyms
MYO-029
-
Envío
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Sci Rep
Combined detection of inhibitors of the activin receptor signaling pathways (IASPs) by means of LC-HRMS/MS for human doping control. [Abstract]2025 Jun 6;15(1):19887. PMID: 40481031
Pureza y Documentación
-
Ficha de datos (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Referencias
[1]. P Singh, et al. Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO-029 Antibody for Muscular Dystrophy. Clin Transl Sci. 2016 Dec;9(6):302-310. [Content Brief]
[2]. Kathryn R Wagner, et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol. 2008 May;63(5):561-71. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Stamulumab Related Classifications
HY-P99588 Related Classifications
Powered by Bioz